# STABILITY STUDY OF A 10% SODIUM BENZOATE ORAL SOLUTION



A. Castro Balado<sup>1\*</sup>, A. Bayón Fernández<sup>2</sup>, I. Adán Barrientos<sup>2</sup>, J.M. Giráldez Montero<sup>1</sup>, I. Varela Rey<sup>1</sup>,

A. Fernández Ferreiro<sup>2</sup>, M. González Barcia<sup>1</sup>, I. Zarra Ferro<sup>1</sup>

\*ana.castro.balado@sergas.es



¹PHARMACY DEPARTMENT. UNIVERSITY CLINICAL HOSPITAL SANTIAGO DE COMPOSTELA (SERGAS) (CHUS)

3PC-005

A16

FACULTY OF PHARMACY-UNIVERSITY OF SANTIAGO DE COMPOSTELA USC, PHARMACY AND PHARMACEUTICAL TECHNOLOGY DEPARTMENT, SPAIN.


## **BACKGROUND**


Defects in the **urea cycle** are genetic diseases in which ammonia is accumulated. **Sodium benzoate** (SB) is conjugated with glycine giving rise to hippurate, excreted in the urine. Currently, no oral sodium benzoate preparation is commercialized.

## **OBJECTIVE**

To evaluate the stability of an **oral solution of 10% sodium benzoate** at two different storage conditions for the treatment of urea cycle disorders.


#### **METHODS**






All absorbance measurements were obtained with a Shimadzu® spectrophotometer model UVmini-1240 UV-Vis at **223 nm**.

#### **RESULTS**





Average degradation (%)		
Day	Refrigerated (2-8 °C)	Room temperature
7	2.82	1.49
30	3.48	2.55

After 30 days, no **colour** change, **opacity** or **precipitation** were observed. In all test solutions, **pH**-values remained unchanged.

# **CONCLUSION**

The 10% Sodium benzoate oral solution, used in urea cycle defects in pediatric patients, is physically and chemically stable when stored protected from light at room temperature or refrigerated (5°C±3°C) for at least 30 days.









